$MNKD Mannkind has only spent pennies on R&D shelving it's valuable Technosphere Inhaled Drug Delivery Platform, choosing instead to spend its capital supporting a failed commercialization effort for Afrezza. It's time for Mannkind to downsize or eliminate its commercial organization by getting rid of many of its top heavy management jobs, eliminating internal sales reps in favor of a contract sales force or licensing out/sell Afrezza to another company. Just imagine what impact the $9 million Mike wasted ramping up television ad campaign in the 1Q 2019, would have had if it was applied to advance Mannkind's R&D pipeline. It's time to end the nightmare believing Afrezza is going to be Mannkind's pot of gold anytime soon and start focusing on the real pot of gold their inhaled drug delivery platform. Also need new CEO.
  • 1